Visa

(redirected from VRSA)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to VRSA: vancomycin, Mrsa

Visa

1. A document allowing a person to enter, study and/or work in a country in which the person is not a citizen. There are many types of visas; most have time limits and restrictions. Visa holders ordinarily are not permitted recourse to welfare or other public funds.

2. A financial services company that issues a large share of credit cards and debit cards in the United States and worldwide. It began as a credit card issued by Bank of America that was accepted by multiple merchants, and not simply by a single company. In 1970, Visa became its own company and revolutionized the way for which goods and services are paid, especially at the retail level. Because of Visa, customers may pay with a card almost everywhere and are not required to use cash or check.
References in periodicals archive ?
1): each patient had substantial underlying concurrent conditions that contributed to the illnesses, genetic analysis of these isolates indicates that VRSA was not transmitted to or from another known VRSA patient, and no identified transmission occurred from patients to contacts.
As has been suggested by previously reported cases of VRSA, early identification of these patients is recommended to minimize antimicrobial selective pressure and enhance infection control efforts to reduce the potential for patient-to-patient transmission (5,7).
Now Midland hospitals are on high alert for the superbug and any incidence of VRSA.
CDC recommendations state: "Not all susceptibility testing methods detect VISA and VRSA isolates.
8] CFU/mL) on BHI agar with prolonged incubation, or vancomycin high-salt agar should not be reported as VRSA on a patient's medical record.
Another poster presented by the CDC showed the ability of VRE EVIGENE to detect all six known VRSA (Vancomycin-resistant S.
VersaPoint was founded in March 2000 through a strategic partnership between Amsterdam-based Versatel Telecom (Nasdaq and AEX: VRSA and San Francisco-based NorthPoint Communications (Nasdaq: NPNT).
OTCBB:CYGX) announces the preclinical development of CY403 a antibacterial compound that is specific against all strains of Staphylococcus aureus, especially resistant strains such as MRSA - Methicillin-resistant and VRSA - Vancomycin- resistant, popularly referred to as "superbugs".
This laboratory study demonstrated that CytoGenix CY401 inhibits growth of VRSA, bacteria that are resistant to approved doses of all antibiotic products.
and presented at the conference yesterday, compared the activities of several investigational antibiotics against one of the two strains of VRSA identified to date.